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1. Introduction  
Twenty-seven hospitals in Japan specialize in treatment of muscular dystrophy patients, 
including inpatient care, of which 26 belong to the National Hospital Organization, and the 
other is the National Center of Neurology and Psychiatry. Since 1999, Japanese muscular 
dystrophy research groups investigating nervous and mental disorder have been developing a 
database of cases treated at these 27 institutions. In that regard, we conducted a survey of 
inpatients with muscular dystrophy and other neuromuscular disorders based on data 
collected by the National Hospital Organization and National Center of Neurology and 
Psychiatry. Herein, we examined data obtained between 1999 and 2010 in order to evaluate 
the medical condition of inpatients with muscular dystrophy in Japan.  
2. Subjects and methods 
The database includes numbers of inpatients, gender, age, diagnosis, respiratory condition, 
nutritional state, number of death cases, causes of death, and other relevant findings from 
data collected annually on October 1 every year since 1999. We examined these data using 
longitudinal and horizontal analyses. 
3. Sequential changes in total numbers of inpatients treated at muscular 
dystrophy wards of National Hospital Organization and National Center of 
Neurology and Psychiatry 
The total numbers of inpatients treated at the muscular dystrophy wards of the National 
Hospital Organization and National Center of Neurology and Psychiatry were quite 
consistent during the examination period. The lowest number of inpatients was 2066 in 2007 
and the highest was 2193 in 2003 (Fig. 1). 
3.1 Details regarding number of inpatients 
The number of inpatients with Duchenne muscular dystrophy gradually decreased (882~770) 
every year (Fig. 2), whereas that of those with myotonic dystrophy gradually increased 
(327~411) (Fig. 3). The numbers of inpatients with other types of muscular dystrophy, such  
www.intechopen.com
 
Muscular Dystrophy 
 
248 
 
 “Other muscular dystrophies” includes Becker muscular dystrophy, Fukuyama congenital muscular 
dystrophy, limb-girdle muscular dystrophy, facio-scapulo-humeral muscular dystrophy, Ullrich 
muscular dystrophy, and others. 
“Other neuromuscular disease” includes amyotrophic lateral sclerosis, spinal muscular atrophy, 
hereditary sensory motor neuropathy, congenital myopathy, and others.  
DMD, Duchenne muscular dystrophy; MD, myotonic dystrophy 
Fig. 1. Total numbers of inpatients in muscular dystrophy wards of National Hospital 
Organization and National Center of Neurology and Psychiatry. 
 
The number with Duchenne muscular dystrophy has gradually decreased every year.  
TIV,tracheostomy intermittent ventilation; NPPV, non-invasive positive pressure ventilation 
Fig. 2. Sequential changes in number of inpatients with Duchenne muscular dystrophy and 
rate of mechanical ventilation dependence. 
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as Becker muscular dystrophy (94~105), Fukuyama congenital muscular dystrophy (50~64), 
limb-girdle type muscular dystrophy (185~216), and facio-scapulo-humeral muscular 
dystrophy (64~72) showed some fluctuations. Inpatients with spinal muscular atrophy 
showed a gradual decreasing tendency from 73 in 1999 to 56 in 2010, while those with 
amyotrophic lateral sclerosis increased every year from 29 to 132 (Fig. 4). Other diseases 
encountered in these patients included congenital metabolic disease, mitochondrial disease, 
various types of myopathy, peripheral nerve disease, bone disease, chromosomal 
abnormalities, spinocerebellar ataxia, neonatal period disease sequelae, infectious diseases, 
and others, though their numbers were small and equalled around 10% of all diseases. 
 
The number with myotonic dystrophy has gradually increased every year.  
Fig. 3. Sequential changes in number of inpatients with myotonic dystrophy and rate of 
mechanical ventilation dependence.  
 
The number with amyotrophic lateral sclerosis has gradually increased every year.  
Fig. 4. Sequential changes in number of inpatients with amyotrophic lateral sclerosis.  
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3.2 Sequential changes in respiratory care for inpatients and rate of mechanical 
ventilation dependence  
The rate of mechanical ventilation use in 1999 was 37.9%, which gradually increased to 
62.9% in 2010 (Fig. 5), while that for Duchenne muscular dystrophy patients in 1999 was 
58.7% and gradually increased to 85.1% in 2010 (Fig. 2). Although the total number of 
inpatients with Duchenne muscular dystrophy gradually decreased, cases of non-invasive 
ventilation gradually increased and tracheostomy cases were also slightly increased. The 
rate of mechanical ventilation use for myotonic dystrophy patients in 1999 was 20.3%, which 
gradually increased to 55.7% in 2010 (Fig. 3). 
 
The rate of mechanical ventilation use in 1999 was 37.9%, which gradually increased to 62.9% in 2010.  
Fig. 5. Sequential changes in respiratory care for inpatients and rate of mechanical 
ventilation dependence.  
3.3 Analysis of mean age of inpatients  
3.3.1 Changes in age distribution of inpatients in muscular dystrophy wards 
The age distribution of inpatients in muscular dystrophy wards in 1999 showed 2 peaks. 
Those with Duchenne muscular dystrophy largely constituted the younger age peak in 
the 20s, while those with myotonic dystrophy larger constituted the older age peak in the 
50s. These age peaks shifted to a higher range and became slightly flattened in 2009 (Fig. 
6). 
3.3.2 Sequential changes in mean age of inpatients  
The mean age of the inpatients in 1999 was 36.6 years old, which gradually increased to 
45.3 years old in 2010. That of Duchenne muscular dystrophy patients in 1999 was 23.6 
years old, which gradually increased to 29.4 years old in 2010, while that of myotonic 
dystrophy patients changed only slightly from 51.4 years old in 1999 to 53.6 years old in 
2010 (Fig. 7). 
% of respiration 
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Upper: 1999. Lower: 2009. The age distribution of inpatients in muscular dystrophy wards shifted to a 
higher range over time.  
 
 
 
Fig. 6. Changes in age distribution of inpatients in muscular dystrophy wards.  
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The mean age of the inpatients was gradually increased. DMD, Duchenne muscular dystrophy; MD, 
myotonic dystrophy; ALS, amyotrophic lateral sclerosis 
Fig. 7. Sequential changes in mean age of inpatients.  
Gradual changes in age distribution of inpatients with Duchenne muscular dystrophy was 
observed. The age peak in 1999 shifted to a higher range and became slightly flattened in 
2009 (Fig. 8). 
 
Fig. 8. Changes in age distribution of inpatients with Duchenne muscular dystrophy. 
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3.4 Sequential changes in numbers of patients receiving oral nutrition and those with 
Duchenne muscular dystrophy who underwent a percutaneous endoscopic 
gastrostomy  
The proportion of patients with Duchenne muscular dystrophy receiving oral nutrition in 
1999 was 95.1%, which gradually decreased to 70.6% in 2010. In contrast, the number who 
required tube feeding, including a nasal nutrition tube and undergoing a percutaneous 
endoscopic gastrostomy, gradually increased to 107 in 2010.  
 
 
PEG, percutaneous endoscopic gastrostomy 
Fig. 9. Sequential changes in numbers of Duchenne muscular dystrophy patients and those 
who underwent an endoscopic gastrostomy patients receiving oral nutrition.  
3.5 Death case analysis  
The total number of deaths reported from 2000 to 2010 was 1307, which ranged from 95-174 
annually in a variable pattern (Fig. 10). The number of Duchenne muscular dystrophy 
patients who died was 409, while that of myotonic dystrophy patients was 363. 
The mean age of death among Duchenne muscular dystrophy patients was 26.7 years old in 
2000, which gradually increased to 35.1 years old by 2010. On the other hand, the mean age 
of death for myotonic dystrophy patients was 59.0 years old in 2000 and 59.1 years old in 
2010, which was not significantly different (Fig. 10). 
The most frequent cause of death among Duchenne muscular dystrophy patients was heart 
failure, accounting for 47%. As for myotonic dystrophy patients, the most frequent cause 
was respiratory disorders, such as respiratory failure and respiratory tract infection, which 
accounted for 64% (Fig. 11). 
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DMD, Duchenne muscular dystrophy; MD, myotonic dystrophy 
Fig. 10. Sequential numbers of deaths and mean age at death reported to the database. 
 
The most frequent cause of death among Duchenne muscular dystrophy patients was heart failure. In 
contrast, that of myotonic dystrophy patients was respiratory disorder. 
DMD, Duchenne muscular dystrophy; MD, myotonic dystrophy 
Fig. 11. Causes of death among Duchenne muscular dystrophy and myotonic dystrophy 
patients (2000~2010).  
3.6 Proportional changes in numbers of inpatients in muscular dystrophy wards of 
each institution 
Twenty-seven hospitals in Japan specialize in treatment of muscular dystrophy patients are 
not same in terms of types of muscular dystrophy of inpatient, disease severity, and actual 
care. Fig. 12 shows the proportion of inpatients by each institution. The upper figure, which 
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shows the proportion in 1999, is arranged according to rate of Duchenne muscular 
dystrophy inpatients. There were significant differences in regard to the proportion of 
inpatients among the institutions in 1999, which changed over time. In 2009, the proportion 
of inpatients with amyotrophic lateral sclerosis was notable. 
 
 
 
 
 
Upper: 1999. Lower: 2009. A~AZ represent the individual institution. Institute AZ, which had lowest 
rate of DMD patients among institutions in 1999, has no DMD patient in 2009.  
DMD, Duchenne muscular dystrophy; MD, myotonic dystrophy; ALS, amyotrophic lateral sclerosis 
 
Fig. 12. Changes in proportions of inpatients in muscular dystrophy wards of each institution 
3.7 Sequential changes in respiratory conditions of Duchenne muscular dystrophy 
patients at each institution (1999~2009). 
The total number of Duchenne muscular dystrophy patients treated from 1999 to 2009 was 
1427. The changes in motor function of the patients were nearly uniform, whereas the 
therapeutic respiratory conditions varied among the institutions.  
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Figure 13 presents the respiratory conditions of the patients for the 11-year period from 
1999 to 2009. In the 10s, almost patients keep voluntary respiratory function. In the 20s, 
various respiratory patterns are observed, which seem not to be different among the 
institutions. In more than 30s, there were apparent differences among the institutions. 
Some institutes have no tracheostomy older patients, which generation is generally 
supposed not to be compensated by non-invasive positive pressure ventilation and use 
tracheotomy ventilation. 
 
 
 
 
 
 
 
 
Each cluster indicates a single institution. The vertical axis indicates the course of a single Duchenne 
muscular dystrophy patient. The respiratory conditions of older patients differed among the 
institutions. For example, the left oval indicates a tracheostomy case and the right oval a non-invasive 
positive pressure ventilation case.  
TIV,tracheostomy intermittent ventilation; NPPV, non-invasive positive pressure ventilation 
 
 
 
Fig. 13. Sequential changes in respiratory conditions of Duchenne muscular dystrophy 
patients treated at each institution (1999~2009).  
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4. Conclusion 
Wards for patients with muscular dystrophy were originally established in Japan in 1964 
and then gradually expanded throughout the country. As a result, approximate 2500 beds 
are now provided among 27 institutions. In the early days, many of the patients were boys 
with Duchenne muscular dystrophy, who received education in schools near the hospital 
where they received care. However, over time, regular public elementary and junior high 
schools began to accept disabled children, and such patients were then able to receive an 
education at schools in their home town. Thus, cases of admission for the purpose of 
education gradually decreased.  
On the other hand, progress in therapeutic strategies for respiratory failure (American 
Thoracic Society Documents, 2004), heart failure (Ishikawa, 1999; Matsumura, 2010) and 
other complications associated with muscular dystrophy prolonged the life span of affected 
individuals (Bushby 2010a, b). Now, most inpatients admitted to a muscular dystrophy 
ward have a severe general condition and many are assisted by mechanical ventilation 
(Tatara, 2008). In addition, in terms of nutritional control (American Thoracic Society 
Documents, 2004; Bushby 2010b), the number of percutaneous endoscopic gastrostomy 
patients with Duchenne muscular dystrophy has gradually increased.  
Thus, the age and disease severity of inpatients have been gradually progressed with this 
changing environment. And social welfare systems related to muscular dystrophy wards in 
Japan also have been changing during this research. The social role of wards for inpatients 
with muscular dystrophy has been changing. The gradual increase of number of inpatients 
with amyotrophic lateral sclerosis means that the ward for patients with muscular 
dystrophy is no longer only for patients with muscular dystrophy. Present wards have 
purpose for care and treatment for severe disabilities, not limited to patients with muscular 
dystrophy. 
There are some reports concerned with prognosis of patients with Duchenne muscular 
dystrophy from single institution belonging to the National Hospital Organization 
(Ishikawa, 2011; Matsumura, 2011). Just as these reports, we showed the increasing mean 
age of death among Duchenne muscular dystrophy patients. Although the most frequent 
cause of death among Duchenne muscular dystrophy patients was heart failure, the 
progression for cardioprotection therapy to cardiomyopathy (Ishikawa, 1999; Matsumura, 
2010) improved the prognosis.  
However, the present findings showed that there are apparent differences in regard to the 
proportion of inpatients and therapeutic conditions among institutions. Hereafter, these 
differences will be more remarkable. So far almost same therapy has been offered among the 
National Hospital Organization and National Center of Neurology and Psychiatry. 
However, these conditions will not continue and may influence the prognosis of patients 
with muscular dystrophy in Japan.  
Social role of wards for patients with muscular dystrophy at establishment, offering patients 
with muscular dystrophy opportunities of education and treatment, has changed into 
offering severe disabilities care and treatment. We should consider how to manage these 
conditions. 
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Institutions specializing in muscular dystrophy treatment in Japan (Fig.14) 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 14. Institutions specializing in muscular dystrophy treatment in Japan  
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National Hospital Organization: 
- Asahikawa Medical Center, Yakumo Hospital, Aomori National Hospital, 
- Akita National Hospital, Nishitaga National Hospital, East Saitama National Hospital, 
- Shimoshizu National Hospital, National Hakone Hospital, Niigata National Hospital,  
- Iou National Hospital, Nagara Medical Center, Suzuka National Hospital,  
- Nara Medical Center, Utano Hospital, Toneyama National Hospital,  
- Hyogo-cyuo National Hospital, Hiroshima-Nishi Medical Center, Matsue Medical 
Center, 
- Tokushima National Hospital, Oomuta Hospital, Nagasaki Kawatana Medical Center,  
- Kumamoto Saishunso National Hospital, Nishibeppu National Hospital,  
- Miyazaki Higashi Hospital, Minami Kyushu National Hospital, Okinawa National 
Hospital  
National Center of Neurology and Psychiatry  
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